Allena Pharmaceuticals Inc. [NASDAQ: ALNA] gained 9.00% on the last trading session, reaching $0.23 price per share at the time. The company report on July 5, 2022 that Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock.
The date of the rescheduled special meeting, and the new record date for determining the Allena stockholders entitled to vote thereat, will be determined in the near future, and will be will be included in supplemental proxy materials to be filed with the SEC and distributed to stockholders promptly after the new record date.
Allena Pharmaceuticals Inc. represents 107.72 million in outstanding shares, while the company has a total market value of $22.70 million with the latest information. ALNA stock price has been found in the range of $0.217 to $0.243.
If compared to the average trading volume of 27.19M shares, ALNA reached a trading volume of 39949654 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Allena Pharmaceuticals Inc. [ALNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALNA shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALNA stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Allena Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 01, 2020. While these analysts kept the previous recommendation, Credit Suisse raised their target price to Outperform. The new note on the price target was released on July 10, 2019, representing the official price target for Allena Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $20, while Robert W. Baird analysts kept a Outperform rating on ALNA stock.
The Average True Range (ATR) for Allena Pharmaceuticals Inc. is set at 0.05 The Price to Book ratio for the last quarter was 1.77, with the Price to Cash per share for the same quarter was set at 0.09.
Trading performance analysis for ALNA stock
Allena Pharmaceuticals Inc. [ALNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.42. With this latest performance, ALNA shares gained by 104.81% in over the last four-week period, additionally sinking by -54.40% over the last 6 months – not to mention a drop of -80.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALNA stock in for the last two-week period is set at 62.57, with the RSI for the last a single of trading hit 64.91, and the three-weeks RSI is set at 59.51 for Allena Pharmaceuticals Inc. [ALNA]. The present Moving Average for the last 50 days of trading for this stock 0.1370, while it was recorded at 0.2047 for the last single week of trading, and 0.4638 for the last 200 days.
Allena Pharmaceuticals Inc. [ALNA]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -234.88, with Return on Assets sitting at -132.08.
Allena Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.00.
An analysis of insider ownership at Allena Pharmaceuticals Inc. [ALNA]
There are presently around $2 million, or 7.60% of ALNA stock, in the hands of institutional investors. The top three institutional holders of ALNA stocks are: TRV GP II, LLC with ownership of 2,790,964, which is approximately 0% of the company’s market cap and around 1.15% of the total institutional ownership; VANGUARD GROUP INC, holding 2,581,193 shares of the stock with an approximate value of $0.59 million in ALNA stocks shares; and FRAZIER MANAGEMENT LLC, currently with $0.23 million in ALNA stock with ownership of nearly -38.276% of the company’s market capitalization.
Positions in Allena Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 11 institutional holders increased their position in Allena Pharmaceuticals Inc. [NASDAQ:ALNA] by around 127,767 shares. Additionally, 17 investors decreased positions by around 9,069,641 shares, while 8 investors held positions by with 1,108,181 shares. The mentioned changes placed institutional holdings at 8,089,227 shares, according to the latest SEC report filing. ALNA stock had 4 new institutional investments in for a total of 29,795 shares, while 7 institutional investors sold positions of 5,330,515 shares during the same period.